Lack of association between the interleukin 6 gene -174G>C polymorphism and colorectal cancer: Evidence from a meta-analysis

Genetics and Molecular Research

Volumn 12, Issue 3, 2013, Pages 2205-2214

  Hu, J J ^a   Wang, Z T ^a   Zhong, J ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Association signal; Colorectal cancer; IL6 gene; Meta analysis; Polymorphism

Indexed keywords

CYSTEINE; GLYCINE; INTERLEUKIN 6;

ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; COLORECTAL CANCER; ETHNICITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPING TECHNIQUE; HUMAN; INTERLEUKIN 6 GENE; QUANTITATIVE ANALYSIS;

CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENES, DOMINANT; GENES, RECESSIVE; GENETIC ASSOCIATION STUDIES; HOMOZYGOTE; HUMANS; INTERLEUKIN-6; MODELS, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; POPULATION;

EID: 84880114095     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2013.July.8.2     Document Type: Article

References (33)

1. Abuli A, Fernandez-Rozadilla C, Alonso-Espinaco V, Munoz J, et al. (2011). Case-control study for colorectal cancer genetic susceptibility in EPICOLON: previously identified variants and mucins. BMC Cancer 11: 339.
2. Cacev T, Jokic M, Loncar B, Krizanac S, et al. (2010). Interleukin-6-174 G/C polymorphism is not associated with IL-6 expression and susceptibility to sporadic colon cancer. DNA Cell Biol. 29: 177-182.
3. Chung YC and Chang YF (2003). Serum interleukin-6 levels reflect the disease status of colorectal cancer. J. Surg. Oncol. 83: 222-226.
4. Cohn LD and Becker BJ (2003). How meta-analysis increases statistical power. Psychol. Methods 8: 243-253.
5. Collet JP, Sharpe C, Belzile E, Boivin JF, et al. (1999). Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br. J. Cancer 81: 62-68.
6. Galizia G, Orditura M, Romano C, Lieto E, et al. (2002). Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin. Immunol. 102: 169-178.
7. Hemminki K, Lorenzo BJ and Forsti A (2006). The balance between heritable and environmental aetiology of human disease. Nat. Rev. Genet. 7: 958-965.
8. Higgins JP and Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat. Med. 21: 1539-1558.
9. Higgins JP, Thompson SG, Deeks JJ and Altman DG (2003). Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
10. Hsu CP and Chung YC (2006). Influence of interleukin-6 on the invasiveness of human colorectal carcinoma. Anticancer Res. 26: 4607-4614.
11. Jemal A, Siegel R, Xu J and Ward E (2010). Cancer statistics, 2010. CA Cancer J. Clin. 60: 277-300.
12. Kinoshita T, Ito H, and Miki C (1999). Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer 85:2526-2531.
13. Knupfer H and Preiss R (2010). Serum interleukin-6 levels in colorectal cancer patients-a summary of published results. Int. J. Colorectal Dis. 25: 135-140.
14. Kury S, Buecher B, Robiou-du-Pont S, Scoul C, et al. (2008). Low-penetrance alleles predisposing to sporadic colorectal cancers: a French case-controlled genetic association study. BMC Cancer 8: 326.
15. Landi S, Moreno V, Gioia-Patricola L, Guino E, et al. (2003). Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res. 63: 3560-3566.
16. Potter JD, Slattery ML, Bostick RM and Gapstur SM (1993). Colon cancer: a review of the epidemiology. Epidemiol. Rev. 15: 499-545.
17. Rhodes JM and Campbell BJ (2002). Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. Trends Mol. Med. 8: 10-16.
18. Ruano-Ravina A, Perez-Rios M and Barros-Dios JM (2008). Population-based versus hospital-based controls: are they comparable? Gac. Sanit. 22: 609-613.
19. Salanti G, Sanderson S and Higgins JP (2005). Obstacles and opportunities in meta-analysis of genetic association studies. Genet. Med. 7: 13-20.
20. Schneider MR, Hoeflich A, Fischer JR, Wolf E, et al. (2000). Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. Cancer Lett. 151: 31-38.
21. Schottelius AJ and Dinter H (2006). Cytokines, NF-kappaB, microenvironment, intestinal inflammation and cancer. Cancer Treat. Res. 130: 67-87.
22. Slattery ML, Wolff RK, Herrick JS, Caan BJ, et al. (2007). IL6 genotypes and colon and rectal cancer. Cancer Causes Control 18: 1095-1105.
23. Slattery ML, Wolff RK, Curtin K, Fitzpatrick F, et al. (2009). Colon tumor mutations and epigenetic changes associated with genetic polymorphism: insight into disease pathways. Mutat. Res. 660: 12-21.
24. Smalley W, Ray WA, Daugherty J and Griffin MR (1999). Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch. Intern. Med. 159: 161-166.
25. Terry CF, Loukaci V and Green FR (2000). Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J. Biol. Chem. 275: 18138-18144.
26. Theodoropoulos G, Papaconstantinou I, Felekouras E, Nikiteas N, et al. (2006). Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer. World J. Gastroenterol. 12: 5037-5043.
27. Tsilidis KK, Helzlsouer KJ, Smith MW, Grinberg V, et al. (2009). Association of common polymorphisms in IL10, and in other genes related to inflammatory response and obesity with colorectal cancer. Cancer Causes Control 20: 1739-1751.
28. Vagefi PA and Longo WE (2005). Colorectal cancer in patients with inflammatory bowel disease. Clin. Colorectal Cancer 4: 313-319.
29. Vasku A, Vokurka J and Bienertova-Vasku J (2009). Obesity-related genes variability in Czech patients with sporadic colorectal cancer: preliminary results. Int. J. Colorectal Dis. 24: 289-294.
30. Vogel U, Christensen J, Dybdahl M, Friis S, et al. (2007). Prospective study of interaction between alcohol, NSAID use and polymorphisms in genes involved in the inflammatory response in relation to risk of colorectal cancer. Mutat. Res. 624: 88-100.
31. Wilkening S, Tavelin B, Canzian F, Enquist K, et al. (2008). Interleukin promoter polymorphisms and prognosis in colorectal cancer. Carcinogenesis 29: 1202-1206.
32. Yeh KY, Li YY, Hsieh LL, Chen JR, et al. (2010). The-174 G/C polymorphism in interleukin-6 (IL-6) promoter region is associated with serum IL-6 and carcinoembryonic antigen levels in patients with colorectal cancers in Taiwan. J. Clin. Immunol. 30: 53-59.
33. Yu K, Zhang J, Zhang J, Dou C, et al. (2010). Methionine synthase A2756G polymorphism and cancer risk: a metaanalysis. Eur. J. Hum. Genet. 18: 370-378.